Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension

• DOI: 10.1002/hep.28547
• Publication Date: 2016-03-19T06:59:42Z
• Authors: Julien Bissonnette; Juan Carlos Garci...; Agustín Albillos; Fanny Turon; Carlos Ferreira; Luis Tellez; Jean‐Charles Nault; Nicolas Carbonell; Jean‐Paul Cervoni; Mohamed Abdel Rehim; Annie Sibert; Louis Bouchard; Pierre Perreault; Jonel Trebicka; Félix Trottier‐Te...; Pierre‐Emmanuel R...; Dominique‐Charles...; Aurélie Plessier
• Keywords: Hepatic Encephalopathy; Liver disease; Portal vein thrombosis

Idiopathic noncirrhotic portal hypertension is a heterogeneous group of diseases characterized by in the absence cirrhosis. The efficacy and safety transjugular intrahepatic portosystemic shunt (TIPS) this population are unknown. charts patients with idiopathic undergoing TIPS seven centers between 2000 2014 were retrospectively reviewed. Forty-one included. Indications for recurrent variceal bleeding (n = 25) refractory ascites 16). Patients categorized according to presence 27) or 14) significant extrahepatic comorbidities. Associated conditions hematologic, prothrombotic, neoplastic, immune, exposure toxins. During follow-up (mean 27 ± 29 months), rebleeding occurred 7/25 (28%), including three early thrombosis stent. Post-TIPS overt hepatic encephalopathy was present 14 (34%). Eleven died, five due liver disease complications procedure six because associated complicated hemoperitoneum four (10%), which fatal one case. Serum creatinine (P 0.005), as indication 0.04), comorbidities 0.01) at time death. Mortality higher ≥100 μmol/L < 0.001).In who have normal kidney function do not severe conditions, an excellent option treat hypertension. (Hepatology 2016;64:224-231).